Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.
Antonio De VincentisDaphne D'AmatoLaura CristoferiAlessio GerussiFederica MalinvernoAna LleoFrancesca ColapietroFabio MarraAndrea GalliCecilia FioriniBarbara CocoMaurizia Rossana BrunettoGrazia Anna NiroRosa CotugnoCarlo SaittaRaffaele CozzolongoFrancesco LositoEdoardo Giovanni GianniniSara LabancaMarco MarzioniGiulia MarconiAnna MorgandoRinaldo PellicanoEster VanniNora CazzagonAnnarosa FloreaniLuchino ChessaOlivia MorelliLuigi MuratoriAdriano PellicelliMaurizio PompiliFrancesca Romana PonzianiAnnalisa TortoraFloriano RosinaMaurizio RusselloMariarita CannavòLoredana SimoneSilvia StoratoMauro ViganòLudovico AbenavoliMaria D'AntòElisabetta DegasperiMarco DistefanoGaetano ScifoTeresa ZolfinoVincenza CalvarusoGiuseppe CuccoreseValeria Pace PalittiRodolfo SaccoGaetano BertinoEvelise FrazzettoDomenico AlvaroGiacomo MulinacciAndrea PalermoMiki ScaravaglioFrancesca TerraccianiGiovanni GalatiVincenzo RoncaMassimo ZuinErnesto ClaarAntonio IzziAntonio PicardiInvernizzi PietroUmberto Vespasiani-GentilucciMarco Carbonenull nullPublished in: Liver international : official journal of the International Association for the Study of the Liver (2022)
An accurate baseline assessment is crucial to select cirrhotic patients who can benefit from OCA. Although OCA is effective in one third of cirrhotics, bilirubin level ≥1.4 mg/dl should discourage from its use.
Keyphrases